DexCom, Inc. (NASDAQ:DXCM) Stock Holdings Lifted by GDS Wealth Management

GDS Wealth Management increased its holdings in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 148.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 135,815 shares of the medical device company's stock after purchasing an additional 81,045 shares during the quarter. GDS Wealth Management's holdings in DexCom were worth $9,105,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of DXCM. Envestnet Portfolio Solutions Inc. raised its holdings in DexCom by 2.3% in the first quarter. Envestnet Portfolio Solutions Inc. now owns 26,721 shares of the medical device company's stock valued at $3,706,000 after acquiring an additional 601 shares in the last quarter. Quantbot Technologies LP acquired a new stake in shares of DexCom during the first quarter worth $853,000. Empowered Funds LLC grew its position in DexCom by 30.7% in the 1st quarter. Empowered Funds LLC now owns 5,518 shares of the medical device company's stock valued at $765,000 after buying an additional 1,295 shares during the last quarter. Meeder Advisory Services Inc. increased its stake in shares of DexCom by 9.9% during the first quarter. Meeder Advisory Services Inc. now owns 5,295 shares of the medical device company's stock worth $734,000 after acquiring an additional 476 shares during the period. Finally, Williams Jones Wealth Management LLC. raised its stake in shares of DexCom by 11.1% during the 1st quarter. Williams Jones Wealth Management LLC. now owns 23,588 shares of the medical device company's stock worth $3,272,000 after buying an additional 2,350 shares in the last quarter. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, COO Jacob Steven Leach sold 746 shares of the company's stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the transaction, the chief operating officer now directly owns 264,915 shares of the company's stock, valued at approximately $18,318,872.25. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other DexCom news, COO Jacob Steven Leach sold 746 shares of the firm's stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the sale, the chief operating officer now owns 264,915 shares in the company, valued at approximately $18,318,872.25. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Sadie Stern sold 426 shares of the business's stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $29,457.90. Following the transaction, the executive vice president now owns 75,451 shares of the company's stock, valued at $5,217,436.65. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 0.30% of the stock is currently owned by company insiders.

DexCom Stock Up 0.4 %

DXCM stock traded up $0.29 during midday trading on Monday, hitting $70.25. 2,863,089 shares of the company's stock were exchanged, compared to its average volume of 3,902,535. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00. The firm has a 50 day moving average price of $69.66 and a 200-day moving average price of $93.10. The stock has a market capitalization of $27.44 billion, a price-to-earnings ratio of 42.54, a price-to-earnings-growth ratio of 2.15 and a beta of 1.17.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on DXCM shares. Barclays decreased their price target on DexCom from $138.00 to $113.00 and set an "equal weight" rating on the stock in a research note on Monday, July 29th. Baird R W lowered DexCom from a "strong-buy" rating to a "hold" rating in a research note on Friday, July 26th. Stifel Nicolaus increased their price target on shares of DexCom from $90.00 to $100.00 and gave the stock a "buy" rating in a research note on Friday, August 23rd. Sanford C. Bernstein upped their price target on DexCom from $82.00 to $86.00 and gave the stock an "outperform" rating in a research note on Friday, October 25th. Finally, JPMorgan Chase & Co. lifted their price objective on DexCom from $75.00 to $85.00 and gave the company a "neutral" rating in a research note on Friday, October 25th. Seven equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, DexCom presently has a consensus rating of "Moderate Buy" and an average target price of $104.59.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.